-
Mashup Score: 3
— Based on the results of the ODYSSEY Outcomes trial, ICER has calculated two updated value-based price benchmarks, net of rebates and discounts, for alirocumab in patients with a recent acute coronary event: $2,300-$3,400 per year if used to treat all patients who meet trial eligibility criteria, and $4,500-$8,000 per year if used to treat […]
Source: ICERCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1ICER Publishes White Paper Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage - ICER - 2 year(s) ago
Informed by expert input from rare disease patient groups and other stakeholders, White Paper highlights ongoing need for incentives to drive innovation in rare disease treatments, particularly treatments for the smallest patient groups.
Source: ICERCategories: Latest Headlines, Rare DiseaseTweet-
RT @icer_review: ICER Publishes White Paper Evaluating Reforms to Orphan Drug Development, Pricing, and Coverage: https://t.co/dsxRW45Yg8
-
-
Mashup Score: 2
Report will be subject of Midwest CEPAC meeting in August 2022; Draft Scoping Document open to public comment until February 24, 2022.
Source: ICERCategories: Latest Headlines, Rare DiseaseTweet-
As we prepare comments on @icer_review scoping document, we should not have to spend time correcting misinformation frm a CDC ALS Registry rept. Numbers matter. CDC clarity matters. This is an example of an expensive registry shooting us in the foot again. https://t.co/TUHDRtS7ol
-
-
Mashup Score: 1
Public comment period now open until March 3, 2022; Requests to make oral comment during public meeting also being accepted.
Source: ICERCategories: General Medicine News, Latest HeadlinesTweet-
ICER Releases Draft Evidence Report on Treatments for COVID-19 - ICER https://t.co/llyQCDkH45
-
-
Mashup Score: 1ICER Publishes Final Evidence Report and Policy Recommendations on Aducanumab for Alzheimer’s Disease - ICER - 2 year(s) ago
Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net health benefit.
Source: ICERCategories: Hem/Oncs, Latest HeadlinesTweet-
@barttels2 @ProfRobHoward @MadhavThambiset @TheWonkologist @CMSGov @biogen US @icer_review ’s health-benefit price benchmark (HBPB) range for aducanumab is $3,000-$8,400 per year for patients with early Alz' disease https://t.co/aEqS6ZuhQP @oncology_bg
-
-
Mashup Score: 0
The evidence suggests that inclisiran can substantially lower LDL-C with limited safety concerns, and with a less frequent regimen that may enhance therapy adherence; ICER recommends an annual health-benefit price benchmark range of $3,600-$6,000. Bempedoic acid provides a new oral treatment option that may be helpful particularly for patients who are not able to take […]
Source: ICERCategories: Hem/Oncs, Latest HeadlinesTweet-
3/n ... This is because the highly reputed/independent US org @icer_review conducted a detailed CE analysis of Inliciran and Bempedoic Acid https://t.co/4pV4XGcRB0 earlier in the year, and their findings are at complete odds with what NICE is stating
-
-
Mashup Score: 0ICER to Assess Gene Therapy for Beta Thalassemia - ICER - 2 year(s) ago
Report will be subject of New England CEPAC meeting in June 2022; Draft Scoping Document open to public comment until December 16, 2021.
Source: ICERCategories: Hem/Oncs, Latest HeadlinesTweet-
The Institute for Clinical and Economic Review @icer_review will assess the effectiveness and value of @bluebirdbio LentiGlobin #GeneTherapy for thalassemia. ICER is inviting public comment on its initial Scoping Document. https://t.co/3RCAFT86SI Get on it #hematology nerds
-
-
Mashup Score: 0Alzheimer's Disease - ICER - 3 year(s) ago
ICER’s analysis on the comparative clinical effectiveness and value of aducanumab (Biogen) for treatment of Alzheimer’s disease. Learn more.
Source: ICERCategories: Latest Headlines, NeurologyTweet-
.@icer_review is hosting a public meeting today to vote on their recent report on aducanumab, the new drug for #Alzheimers disease. Tune in to hear Brian Callaghan, MD, MS, FAAN, provide public comment on behalf of the AAN. https://t.co/SKxYv5KEBa #AANadvocacy https://t.co/JWDZYSC6B1
-
-
Mashup Score: 10
Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, the revised report finds the price range needed to reach standard cost-effectiveness thresholds is $3,000-$8,400, representing an 85%-95% discount from the announced list price.
Source: ICERCategories: Healthcare Professionals, Latest HeadlinesTweet-
More news on #Aduhelm #costeffectiveness via @icer_review Based on QALYs range = $3,000 - $8,400 vs $56,000 list price #ICER report details on different thresholds & social goals https://t.co/uLRLUqdeSW Public mtg 7-15 w @Biogen et al #Alzheimers #pharma #healthcosts #Aging https://t.co/pf8GPR1Wx5
-
-
Mashup Score: 5Our History & Impact | Who We Are | ICER - 3 year(s) ago
ICER objectively evaluates the clinical and economic value of prescription drugs, medical tests, and other health care and health care delivery innovations. Learn more.
Source: ICERCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @MadhavThambiset: https://t.co/DfS0UT48M6 @ProfRobHoward ICER is the closest US equivalent of NICE. From their exec summary of assessmen…
-
-Based Price Benchmark for Alirocumab #PCSK9i - #ICER https://t.co/lXMSSYosnZ